Induction with intravitreal bevacizumab every two weeks in the management of neovascular age-related macular degeneration Academic Article uri icon

Overview

MeSH Major

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal, Humanized
  • Choroidal Neovascularization
  • Macular Degeneration

abstract

  • Biweekly induction with intravitreal bevacizumab for treatment-na├»ve neovascular AMD does not increase initial fluid-free interval or cause significant anatomic and functional benefit compared to monthly induction or immediate prn. There is also the potential development of subretinal fibrosis with biweekly induction.

publication date

  • January 2014

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1016/j.ajo.2014.10.005

PubMed ID

  • 25308787

Additional Document Info

start page

  • 131

end page

  • 7

volume

  • 159

number

  • 1